Zhongchao (ZCMD) Company Report

Analyst Coverage

Research analysts covering Zhongchao.

Recent press releases and 8-K filings for ZCMD.

Zhongchao Inc. Amends Share Consolidation Proposal for Shareholder Vote

ZCMD

Delisting/Listing Issues

Proxy Vote Outcomes

Zhongchao Inc. has issued a supplement and amendment to the notice of its extraordinary general meeting of shareholders, which was adjourned to February 10, 2026, at 9:30 a.m. Eastern Time.
The primary purpose of this amendment is to modify Proposal No. 3, now referred to as the Amended Proposal No. 3, concerning a share consolidation.
The Amended Proposal No. 3 seeks shareholder approval for a share consolidation of Class A and Class B ordinary shares, which can be implemented at any one time or multiple times over a period of up to three years from the meeting date.
The accumulated consolidation ratio for all such share consolidations will be not less than 2:1 nor greater than 250:1.
The main objective of the share consolidation is to regain compliance with Nasdaq's Minimum Bid Price Rule of US$1.00, as the Class A Ordinary Shares closed at US$0.62 on November 25, 2025, to avoid potential delisting. The Board of Directors unanimously recommends shareholders vote in favor of this proposal.

Jan 20, 2026, 10:20 PM

Zhongchao Inc. to hold Extraordinary General Meeting to vote on share capital increase, share consolidation, and voting rights amendment

ZCMD

Delisting/Listing Issues

Proxy Vote Outcomes

Zhongchao Inc. will hold an Extraordinary General Meeting on January 20, 2026, to consider proposals including a share capital increase, a share consolidation, and an amendment to Class B ordinary share voting rights.
One proposal seeks to increase the authorized share capital from US$500,000 to US$20,000,000.
A 1-for-250 (or lesser) share consolidation is proposed to help the company comply with Nasdaq's minimum bid price rule, as its Class A Ordinary Shares closed at US$0.62 on November 25, 2025.
The company also proposes to amend the voting rights of Class B Ordinary Shares, increasing them from 100 votes to 1,000 votes per share, which would raise CEO Weiguang Yang's voting power from 95.21% to 99.50%.
The Board of Directors unanimously recommends voting "FOR" all proposals.

Nov 26, 2025, 9:00 PM

Zhongchao Inc. Reports Q2 2025 Financial Results and Strategic Shift

ZCMD

Earnings

Demand Weakening

New Projects/Investments

Zhongchao Inc. reported a significant financial decline for the six months ended June 30, 2025, with total revenues falling to $5,601,079 from $8,348,329 in the prior year, and a net loss attributable to shareholders of $(965,254) compared to a net income of $90,047 in the same period of 2024, resulting in a basic and diluted loss per share of $(0.04).
The company's gross profit decreased by 42.8% to $2,709,724, and the overall gross margin declined from 56.7% to 48.4%, primarily due to reduced patented drug sales and intensified competition in medical training and education services.
Operationally, Zhongchao Inc. strategically shifted its focus by ceasing its patented pharmaceuticals sales business on June 30, 2025, to concentrate on customized medical courses and training services.
Despite the net loss, net cash provided by operating activities significantly increased to $1,820,881 for the six months ended June 30, 2025, from $809,598 in the prior year, with cash and cash equivalents ending at $8,912,022.

Sep 29, 2025, 8:08 PM

Get instant answers from SEC filings, earnings calls & more